Hib-DTaP-hepatitis B-poliovirus vaccine - GSK
Alternative Names: DTPa-HBV-IPV-Hib vaccine-GSK; DTPa-HBV-IPV/Hib Vaccine-GSK; DTPa-IPV/Hib; GSK 2036874A; GSK 21774; GSK217744; Haemophilus-influenzae-type-b-DTP-acellular-hepatitis-B-poliovirus-vaccine-GSK; Hexavalent combination vaccine - GSK; Hib-DTaP-hepatitis-B-poliovirus-vaccine-SmithKline-Beecham; Hib-DTP-acellular-hepatitis B-poliovirus vaccine - GSK; Hib-DTP-acellular-hepatitis-B-poliovirus-vaccine-SmithKline-Beecham; Infanrix HepB-IPV/Hib; Infanrix HeXa; Infanrix®-IPV/HibLatest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Haemophilus vaccines; Hepatitis B vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
Most Recent Events
- 15 Jul 2020 Launched for Diphtheria (In infants, Prevention) in Russia (IM)
- 15 Jul 2020 Launched for Haemophilus infections (In infants, Prevention) in Russia (IM)
- 15 Jul 2020 Launched for Hepatitis B (In infants, Prevention) in Russia (IM)